Nexalin Technology Inc. (NXLIW)
undefined
undefined%
At close: undefined
0.21
0.00%
After-hours Dec 13, 2024, 03:51 PM EST

Company Description

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China.

It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia.

The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders.

It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia.

The company was incorporated in 2021 and is headquartered in Houston, Texas.

Nexalin Technology Inc.
Nexalin Technology Inc. logo
Country United States
IPO Date n/a
Industry Medical - Devices
Sector Healthcare
Employees 6
CEO Mark White

Contact Details

Address:
1776 Yorktown
Houston, Texas
United States
Website https://www.nexalin.com

Stock Details

Ticker Symbol NXLIW
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001527352
CUSIP Number 65345B110
ISIN Number US65345B1109
Employer ID 27-5566468
SIC Code 3845

Key Executives

Name Position
Mark White President, Chief Executive Officer, Chief Financial Officer & Director
Carolyn Shelton Senior Vice President of Quality, Regulatory & Clinical Affairs
Dr. David Owens M.D. Chief Medical Officer & Director
John Patrick Claude Co-Founder and Director of Engineering & Development
Marilyn Elson Controller

Latest SEC Filings

Date Type Title
Nov 08, 2024 10-Q Quarterly Report
Nov 01, 2024 8-K Current Report
Oct 30, 2024 4 Filing
Oct 02, 2024 4/A [Amend] Filing
Oct 02, 2024 4 Filing
Oct 02, 2024 4 Filing
Sep 25, 2024 4 Filing
Sep 25, 2024 4/A [Amend] Filing
Sep 25, 2024 8-K Current Report
Sep 19, 2024 8-K Current Report